Previous studies have reported abnormal expression levels of UGP2 in various cancer types, including pancreatic ductal carcinoma [12], gallbladder cancer [13], colorectal cancer [14], acute myeloid leukaemia [15], glioma [16], and HCC [17]. This evidence concerns the gene UGP2 and hepatocellular carcinoma.